M
Madrigal Pharmaceuticals, Inc. (MDGL)
NMS – Real Time Price. Currency in USD
510.68
-8.08 (-1.56%)
At close: Mar 27, 2026, 4:00 PM EDT
513.00
+2.32 (0.45%)
After-hours: Mar 27, 2026, 7:41 PM EDT

NMS – Real Time Price. Currency in USD
510.68
-8.08 (-1.56%)
At close: Mar 27, 2026, 4:00 PM EDT
513.00
+2.32 (0.45%)
After-hours: Mar 27, 2026, 7:41 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 4.01 | 6.05 | 10 | |
| Quick ratio | 3.77 | 5.63 | 10 | |
| Debt to Equity | 0.58 | 0.30 | 7.0 | |
| Debt to Assets | 0.28 | 1.04 | 7.0 | |
| Interest coverage | -7.18 | -16.91 | 1.0 | |
| Weighted average score | 7.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | 180M | 958M | 958M |
| Gross Profit | -467K | -527K | 173M | 901M | 901M |
| Operating Income | -294M | -380M | -498M | -300M | -300M |
| Net Income | -295M | -374M | -466M | -288M | -288M |
| EBITDA | -293M | -380M | -497M | -299M | -299M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 119.26 | -28.51 | 5.5 |
| Next quarter | 63.68 | 32.95 | 10 |
| Current year | 54.56 | 65.07 | 10 |
| Next year | 46.48 | 386.69 | 10 |
| Weighted average score | 8.9 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 11.77 | 48.7 | 49.41 | -268.45 | 7.0 |
| Y/Y | 210.77 | 1.42 | 5.17 | -27.11 | 4.8 |
| 3y average | 810.02 | -4.34 | 5.26 | -8.85 | 4.3 |
| 5y average | 885.61 | -10.94 | -2.74 | -13.07 | 3.3 |
| Weighted average score | 4.9 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | Medium | 7.0 |
| Intangible assets | Wide | 8.0 |
| Switching costs | Medium | 7.0 |
| Network effect | None | 1.0 |
| Economies of scale | Narrow | 4.0 |
| Weighted average score | 5.4 | |
Total debt $347.6M significantly exceeds cash reserves ($203.8M), raising financial stability concerns
Total current assets $1.2B exceed Total current liabilities $310.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.6) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-7.2x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$133.1M limits the company's ability to reinvest or pay down debt